Firm announces plans to pursue "strategic alternatives" for its genetic testing, diagnostic products and pharmaceutical intermediates businesses. Management is exploring divestiture, spin-out or management buyout, Genzyme disclosed on May 6. Genzyme will also initiate a $2 billion stock buyback. The initiatives are designed to increase shareholder value, CEO Henri Termeer told analysts
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.